Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer

Cancer Invest. 2017 May 28;35(5):333-344. doi: 10.1080/07357907.2017.1289215. Epub 2017 Apr 3.

Abstract

The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routine clinical practice across the United States. This observational study is designed to enroll 500 patients with previously untreated mRCC from approximately 60 academic and community treatment sites; as of December 7, 2016, 500 patients have enrolled at 54 sites. Key endpoints include real-world data on reasons for treatment initiation and discontinuation; treatment regimens; disease progression; patient-reported outcomes; and healthcare resource utilization in this patient population.

Keywords: Metastatic renal cell carcinoma; Observational study; Patient Reported Outcomes; Real-world data.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Carcinoma, Renal Cell / secondary*
  • Carcinoma, Renal Cell / therapy*
  • Community Health Services / statistics & numerical data
  • Community Health Services / trends*
  • Disease Progression
  • Health Resources / statistics & numerical data
  • Health Resources / trends
  • Humans
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / therapy*
  • Patient Reported Outcome Measures
  • Practice Patterns, Physicians' / trends*
  • Prospective Studies
  • Quality of Life
  • Registries*
  • Research Design
  • Time Factors
  • Treatment Outcome
  • United States